Goldman Sachs analysts added Fresenius Medical (FMS) to the firm’s European Conviction List as part of its monthly update. The firm believes treatment volume growth is inflecting at Fresenius Medical.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical price target raised to EUR 41 from EUR 39 at Barclays
- Fresenius Medical’s Novalung ECMO System selected by Premier
- Fresenius Medical price target raised to EUR 39 from EUR 38.50 at Barclays
- Fresenius Medical price target raised to EUR 37.30 from EUR 35.40 at JPMorgan
- Fresenius Medical ADRs initiated with a Buy at Berenberg